Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > ESC Congress 2024, 30 August - 2 September, London
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by jopatcloon Aug 28, 2024 11:03am
58 Views
Post# 36199381

RE:ESC Congress 2024, 30 August - 2 September, London

RE:ESC Congress 2024, 30 August - 2 September, London  It would be perfect to have FDA 4.0 before !   Maybe ?? FDA V4.0 Dear Friend for ESC 2024 ? Exciting Educational Opportunities at ESC 2024! Now remember health Canada has approved us, FDA won’t be far behind. The visionary Dr. G. Adams and Alvira M. have done the long work that had to be done during all these years for Ventripoint to arrive V4.0 Bravo procurement in healthcare is complex . FDA V4.0 and Sales at any time now Insiders know!
https://www.escardio.org/Congresses-Events/ESC-Congress/About-the-congress

jopatclo wrote:
This afternoon I am travelling to London for introductory meetings with potential collaborators and industry partners who are attending the 2024 ESC Congress. Rather than exhibiting at this year's congress we have arranged meetings to discuss specific opportunities and initiatives. With the introduction of magnet-free sensors, recent Health Canada Medical Device License for VMS+ V4.0 and approval/clearance pending in other key markets we are actively pursuing opportunities to deploy our products.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities